Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach

Leire Dublang1,2, Jarl Underhaug3,4, Marte I Flydal3

  • 1Instituto Biofisika (UPV/EHU, CSIC), Universidad del País Vasco, (UPV/EHU), Barrio Sarriena, 48940 Leioa, Spain.

Cancers
|July 2, 2021
PubMed

Insights

Repurposed drug pinaverium bromide inhibits heat shock protein 70 (Hsp70) and Hsp110 chaperone activity, showing promise as a novel melanoma cancer treatment by inducing apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Heat shock proteins (Hsps) are upregulated in cancers, aiding tumor progression and chemoresistance.
  • Hsp110 and Hsp70 families are implicated in cancer cell survival and treatment resistance.

Purpose of the Study:

  • To identify novel Hsp70 and Hsp110 inhibitors through drug repurposing.
  • To evaluate the toxicity of identified inhibitors against melanoma cancer cells.

Main Methods:

  • Drug repurposing screen targeting Hsp110 (Apg2) and Hsp70.
  • In vitro cytotoxicity assays on melanoma cell lines.
  • Molecular docking and dynamics simulations.

Main Results:

  • Identified compounds that inhibit both Hsp110 and Hsp70 systems.
  • Pinaverium bromide, an antispasmodic drug, demonstrated specific cytotoxicity in melanoma cells.
  • Pinaverium bromide induced apoptosis by inhibiting Hsp70 chaperone and ATPase activity.

Conclusions:

  • Drug repurposing is a viable strategy for discovering Hsp inhibitors.
  • Pinaverium bromide shows potential as a novel therapeutic agent for melanoma.
  • Targeting Hsp70/Hsp110 chaperone activity offers a new avenue for cancer treatment.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K